Know Cancer

or
forgot password

Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biotherapy in Patients With Rheumatoid Arthritis in Daily Practice


Phase 4
18 Years
N/A
Not Enrolling
Both
Rheumatoid Arthritis

Thank you

Trial Information

Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biotherapy in Patients With Rheumatoid Arthritis in Daily Practice


In this retrolective, multicentric study, medical charts of RA patients starting TNFi
between March 2005 and April 2009 were reviewed, with follow-up between 2 and 6 years. The
retention rate was estimated using the Kaplan-Meier method. Comparison between TNFi was done
after adjustment using a Cox model. Factors associated with better retention were identified
by multivariate analysis. Medical charts of all patients with RA starting a first TNFα
inhibitor therapy between March 1, 2005 (start of commercialization of adalimumab in France)
and April 30, 2009 (allowing at least 2 years of follow-up) were systematically reviewed in
detail by 2 rheumatologist investigators


Inclusion Criteria:



- RA defined by the 1987 ACR criteria [18]

- first TNFα inhibitor prescribed in the previously mentioned period

- TNFα inhibitor prescribed as first-line biotherapy

- undergone at least one evaluation in the center after treatment initiation

Exclusion Criteria:

- previously received another biotherapy

- TNFα inhibitor was prescribed in an RCT

- refused to participate

Type of Study:

Observational

Study Design:

Time Perspective: Retrospective

Outcome Measure:

Compare retention rates of adalimumab, etanercept and infliximab administered as first-line biologic therapy in RA

Outcome Time Frame:

2 years

Safety Issue:

No

Principal Investigator

Pfizer CT.gov Call Center

Investigator Role:

Study Director

Investigator Affiliation:

Pfizer

Authority:

France: The Commission nationale de l’informatique et des libertés

Study ID:

NRB1800007

NCT ID:

NCT01692899

Start Date:

June 2011

Completion Date:

September 2011

Related Keywords:

  • Rheumatoid Arthritis
  • Retention Rates
  • of Adalimumab
  • Etanercept and Infliximab
  • as First and Second-Line Biotherapy
  • in Patients with Rheumatoid Arthritis
  • in Daily Practice.
  • TNF inhibitors
  • biotherapy
  • retrospective study
  • Arthritis
  • Arthritis, Rheumatoid
  • Urinary Retention

Name

Location